Sutro Biopharma Inc
STRO
Get informed when a big investor buys or sells
+ FollowMarket Cap$197.9M
Close$
$-0.82
104% downside
Current Fair Value
104% downsideOvervalued by 104% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $197.90 Million |
|---|---|
| Enterprise Value | $160.80 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $-22.49 |
| Beta | 1.52 |
| Outstanding Shares | 16,571,602 |
Return
| Return on Equity | 174.84% |
|---|---|
| Return on Assets | -92.89% |
| Return on Invested Capital | -99.21% |
Valuation & Multiples
| P/E Ratio | -1.17 |
|---|---|
| PEG | -0.5 |
| Price to Sales | 10.24 |
| Price to Book Ratio | -2.92 |
| Enterprise Value to Revenue | 3.52 |
| Enterprise Value to EBIT | -1.14 |
| Enterprise Value to Net Income | -1 |
| Total Debt to Enterprise | 0.11 |
| Debt to Equity | -0.17 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 12, 2026
EPS Estimate
$-2.19
Average shareholder expectationRevenue Estimate
$11.96 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-1.66
Average shareholder expectationRevenue Estimate
$13.61 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | 61,400▲ Infinity% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 107.74%▼ 4171.68% |
|---|---|
| Total Invested | $351.11M▲ 441.87% |
| Investors Holding | 72▲ 11.00% |
ESG Score
No data
About Sutro Biopharma Inc
CEO: William Newell